Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q1 2026 Earnings Presentation
21 slides from Biogaia Ab Class B's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Results
Q1 2026 RESULTS Telephone Conference 7 May 2026 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Financial highlights Q1 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Financial highlights Q1 2026 GROWTH EXCLUDING EBIT FREE CURRENCY EFFECTS MARGIN CASHFLOW 15% 27% 67MSEK 2
Slide 3: Executive Summary Q1 2026
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Executive Summary Q1 2026 • Net sales reached 372.6 MSEK (366.3), with growth excluding currency effects of 15% (2% including currency effects) • Sales in APAC increased by
Slide 4: BioGaia Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks BioGaia Strategy Expansion through Grow Direct Markets the Core Gut Health / Colic Oral Health Immune Health Breakthrough Innovation Foundations People & Culture Invest for
Slide 5: Delivering on Our Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Delivering on Our Strategy • Driving growth of Pediatric and Adult segments • Investing in marketing and sales activities to drive strong growth in direct markets Grow the
Slide 6: BioGaia Protectis Plus: New product launch within Pediatrics
New product launch within Pediatrics BioGaia® Protectis® Plus Launching today Next-generation patented probiotic baby drops, building on BioGaia’s leadership in infant colic and probiotic science. Dual strain innovation combining L. reuteri Protectis® (DSM 17938), the world’s most researched probiot
Slide 7: Launches
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Launches Distributor Country Product BioGaia Sweden BioGaia Prodentis FRESH BREATH lozenges BioGaia Germany BioGaia Gastrus chewable tablets BioGaia Germany BioGaia Gastrus
Slide 8: Key Events
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Events • February 3 results for the fourth quarter would exceed market expectations • February 26 BioGaia signed a renewed distribution agreement with Ewopharma to furt
Slide 9: Growth Excluding Currency Effects by Business Segment Q1
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Growth Excluding Currency Effects by Business Segment Q1 Total Pediatrics Adults +15% +13% +18% 73% share of revenue 26% share of revenue Sales of BioGaia Protectis drops i
Slide 10: Sales per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Segment Sales per Segment Q1 2026 MSEK Q1 Q1 Change Total 1% 2026 2025 excl FX change 26% Pediatrics 272 270 13% 1% Adult Health 98 95 18% 4% 73% Other 2 2 19% 15
Slide 11: Sales per Region
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Region Sales per Region Q1 2026 MSEK Q1 Q1 Change Change 2026 2025 excl FX 44% 39% EMEA 143 124 24% 16% APAC 65 69 6% -7% Americas 165 174 12% -5% Total 373 366 1
Slide 12: Financials
Alexander Kotsinas, CFO Financials 12
Slide 13: Key Financials
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) -1% +2% 268 267 366 373 +4% 97 101 73% 72% 27% 27% Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 13
Slide 14: Sales Bridge
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales Bridge +2% 54 -47 366 373 Q1 2025 Growth excluding Currency Q1 2026 currency effects effect Change 15% -13% 14
Slide 15: Gross Margin per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Gross Margin per Segment Gross margin Q1 2026 Q1 2025 Pediatrics 74% 75% Adult Health 64% 67% Total 72% 73% • Total: The lower gross margin was mainly driven by negative cu
Slide 16: Operating Expenses (OPEX)
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Operating Expenses (OPEX) MSEK Q1 2026 Q1 2025 Change Sales and Marketing -132 -113 17% Research and Development -26 -23 13% Administration -14 -11 24% Other OPEX 6 -24 125
Slide 17: Profit and Loss Statement
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Profit and Loss Statement MSEK Q1 2026 Q1 2025 Change Sales 373 366 2% Gross profit 267 268 -1% Percentage of revenue 72% 73% OPEX -166 -171 -3% EBIT 101 97 4% Percentage o
Slide 18: Cashflow
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Cashflow MSEK Q1 2026 Q1 2025 Change Cash flow from operating activities before 66 81 -15 changes in net working capital Changes in working capital 5 -45 +50 Cash flow from
Slide 19: Concluding Remarks
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Concluding Remarks • The first quarter shows growth excluding currency effects of 15% • Both our pediatric segment (+13% growth excluding currency effects) and adult segmen
Slide 20: Q&A
Q&A
Slide 21: BioGaia
BioGaia.